Antigen recognition by single-domain antibodies: structural latitudes and constraints

References

• Flajnik MF, Deschacht N, Muyldermans S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol. 2011;9:e1001120. doi:10.1371/journal.pbio.1001120.
   PubMed Web of Science ®Google Scholar
• Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341:544–546. doi:10.1038/341544a0.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–448. doi:10.1038/363446a0.
   PubMed Web of Science ®Google Scholar
• Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature. 1995;374:168–173. doi:10.1038/374168a0.
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–1136. doi:10.1038/nbt1142.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, Muyldermans S, Wyns L. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol. 1996;3:803–811.
   PubMedGoogle Scholar
• Stanfield RL, Dooley H, Flajnik MF, Wilson IA. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science. 2004;305:1770–1773. doi:10.1126/science.1101148.
   PubMed Web of Science ®Google Scholar
• Achour I, Cavelier P, Tichit M, Bouchier C, Lafaye P, Rougeon F. Tetrameric and homodimeric camelid IgGs originate from the same igh locus. J Immunol. 2008;181:2001–2009.
   PubMed Web of Science ®Google Scholar
• Eason DD, Litman RT, Luer CA, Kerr W, Litman GW. Expression of individual immunoglobulin genes occurs in an unusual system consisting of multiple independent loci. Eur J Immunol. 2004;34:2551–2558. doi:10.1002/eji.200425224.
   PubMed Web of Science ®Google Scholar
• Griffin LM, Snowden JR, Lawson AD, Wernery U, Kinne J, Baker TS. Analysis of heavy and light chain sequences of conventional camelid antibodies from Camelus dromedarius and Camelus bactrianus species. J Immunol Methods. 2014;405:35–46. doi:10.1016/j.jim.2014.01.003.
   PubMed Web of Science ®Google Scholar
• De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006;103:4586–4591. doi:10.1073/pnas.0505379103.
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Dooley H, Verdino P, Flajnik MF, Wilson IA. Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. J Mol Biol. 2007;367:358–372. doi:10.1016/j.jmb.2006.12.045.
   PubMed Web of Science ®Google Scholar
• Al Qaraghuli MM, Ferro VA. Analysis of the binding loops configuration and surface adaptation of different crystallized single-domain antibodies in response to various antigens. J Mol Recognit. 2017;30:e2592. doi:10.1002/jmr.2592.
   Web of Science ®Google Scholar
• Konning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, Schroter C, Sellmann C, Hock B, Kolmar H. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017;45:10–16. doi:10.1016/j.sbi.2016.10.019.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Smider VV. Distinct antibody species: structural differences creating therapeutic opportunities. Curr Opin Immunol. 2016;40:7–13. doi:10.1016/j.coi.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Zielonka S, Empting M, Grzeschik J, Konning D, Barelle CJ, Kolmar H. Structural insights and biomedical potential of IgNAR scaffolds from sharks. MAbs. 2015;7:15–25. doi:10.4161/19420862.2015.989032.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Spinelli S, Roussel A, Cambillau C. Camelid nanobodies: killing two birds with one stone. Curr Opin Struct Biol. 2015;32:1–8. doi:10.1016/j.sbi.2015.01.001.
   PubMed Web of Science ®Google Scholar
• Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, De Jonge N, Roovers RC, Cambillau C, Spinelli S, Del-Favero J, et al. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. MAbs. 2015;7:693–706. doi:10.1080/19420862.2015.1046648.
   PubMed Web of Science ®Google Scholar
• Deschacht N, De Groeve K, Vincke C, Raes G, De Baetselier P, Muyldermans S. A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. J Immunol. 2010;184:5696–5704. doi:10.4049/jimmunol.0903722.
   PubMed Web of Science ®Google Scholar
• Li X, Duan X, Yang K, Zhang W, Zhang C, Fu L, Ren Z, Wang C, Wu J, Lu R, et al. Comparative analysis of immune repertoires between bactrian camel’s conventional and heavy-chain antibodies. PLoS One. 2016;11:e0161801. doi:10.1371/journal.pone.0161801.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, De Geus B. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol. 2000;37:579–590.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994;7:1129–1135.
   PubMedGoogle Scholar
• Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol. 1997;34:1121–1131.
   PubMed Web of Science ®Google Scholar
• Nguyen VK, Hamers R, Wyns L, Muyldermans S. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000;19:921–930. doi:10.1093/emboj/19.5.921.
   PubMed Web of Science ®Google Scholar
• Nguyen VK, Su C, Muyldermans S. van der Loo W. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics. 2002;54:39–47. doi:10.1007/s00251-002-0433-0.
   PubMed Web of Science ®Google Scholar
• Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci U S A. 2004;101:12444–12449. doi:10.1073/pnas.0403509101.
   PubMed Web of Science ®Google Scholar
• Diaz M, Stanfield RL, Greenberg AS, Flajnik MF. Structural analysis, selection, and ontogeny of the shark new antigen receptor (IgNAR): identification of a new locus preferentially expressed in early development. Immunogenetics. 2002;54:501–512. doi:10.1007/s00251-002-0479-z.
   PubMed Web of Science ®Google Scholar
• Diaz M, Greenberg AS, Flajnik MF. Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: possible role in antigen-driven reactions in the absence of germinal centers. Proc Natl Acad Sci U S A. 1998;95:14343–14348.
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Harriman R, Deng X, Yeung YA, Miles A, Morishige W, Boustany L, Zhu L, Izquierdo SM, Harriman W. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms. MAbs. 2016;8:264–277. doi:10.1080/19420862.2015.1118596.
   PubMed Web of Science ®Google Scholar
• Pinto J, Odongo S, Lee F, Gaspariunaite V, Muyldermans S, Magez S, Sterckx YG. Structural basis for the high specificity of a Trypanosoma congolense immunoassay targeting glycosomal aldolase. PLoS Negl Trop Dis. 2017;11:e0005932. doi:10.1371/journal.pntd.0005932.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Spinelli S, Payan F, Lauwereys M, Wyns L, Muyldermans S, Cambillau C. Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem. 2002;277:23645–23650. doi:10.1074/jbc.M202327200.
   PubMed Web of Science ®Google Scholar
• Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, Wyns L, Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998;17:3512–3520. doi:10.1093/emboj/17.13.3512.
   PubMed Web of Science ®Google Scholar
• Koch-Nolte F, Reyelt J, Schossow B, Schwarz N, Scheuplein F, Rothenburg S, Haag F, Alzogaray V, Cauerhff A, Goldbaum FA. Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J. 2007;21:3490–3498. doi:10.1096/fj.07-8661com.
   PubMed Web of Science ®Google Scholar
• Burgess SG, Oleksy A, Cavazza T, Richards MW, Vernos I, Matthews D, Bayliss R. Allosteric inhibition of Aurora-A kinase by a synthetic VNAR domain. Open Biol. 2016;6:160089. doi:10.1098/rsob.160089.
   Web of Science ®Google Scholar
• Sohier JS, Laurent C, Chevigne A, Pardon E, Srinivasan V, Wernery U, Lassaux P, Steyaert J, Galleni M. Allosteric inhibition of VIM metallo-β-lactamases by a camelid nanobody. Biochem J. 2013;450:477–486. doi:10.1042/BJ20121305.
   PubMed Web of Science ®Google Scholar
• Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L, Muyldermans S. β-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother. 2001;45:2807–2812. doi:10.1128/AAC.45.10.2807-2812.2001.
   PubMed Web of Science ®Google Scholar
• Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010;397:1106–1118. doi:10.1016/j.jmb.2010.01.070.
   PubMed Web of Science ®Google Scholar
• Thanongsaksrikul J, Srimanote P, Maneewatch S, Choowongkomon K, Tapchaisri P, Makino S, Kurazono H, Chaicumpa W. A VHH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem. 2010;285:9657–9666. doi:10.1074/jbc.M109.073163.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. 2001;276:26285–26290. doi:10.1074/jbc.M102107200.
   PubMed Web of Science ®Google Scholar
• Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J, Lam CM, Wang XW, Xin D, Zhang P, et al. Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016;6:27055. doi:10.1038/srep27055.
   PubMed Web of Science ®Google Scholar
• Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schutze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, et al. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Sci Rep. 2017;7:14289. doi:10.1038/s41598-017-14112-6.
   PubMed Web of Science ®Google Scholar
• Unger M, Eichhoff AM, Schumacher L, Strysio M, Menzel S, Schwan C, Alzogaray V, Zylberman V, Seman M, Brandner J, et al. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep. 2015;5:7850. doi:10.1038/srep07850.
   PubMed Web of Science ®Google Scholar
• Oyen D, Srinivasan V, Steyaert J, Barlow JN. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J Mol Biol. 2011;407:138–148. doi:10.1016/j.jmb.2011.01.017.
   PubMed Web of Science ®Google Scholar
• Zhu J, Declercq J, Roucourt B, Ghassabeh GH, Meulemans S, Kinne J, David G, Vermorken AJ, Van de Ven WJ, Lindberg I, et al. Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem J. 2012;448:73–82. doi:10.1042/BJ20120537.
   PubMed Web of Science ®Google Scholar
• Dahms SO, Creemers JW, Schaub Y, Bourenkov GP, Zogg T, Brandstetter H, Than ME. The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers. Sci Rep. 2016;6:34303. doi:10.1038/srep34303.
   PubMed Web of Science ®Google Scholar
• Transue TR, De Genst E, Ghahroudi MA, Wyns L, Muyldermans S. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins. 1998;32:515–522.
   PubMed Web of Science ®Google Scholar
• Chan PH, Pardon E, Menzer L, De Genst E, Kumita JR, Christodoulou J, Saerens D, Brans A, Bouillenne F, Archer DB, et al. Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry. 2008;47:11041–11054. doi:10.1021/bi8005797.
   PubMed Web of Science ®Google Scholar
• De Genst E, Silence K, Ghahroudi MA, Decanniere K, Loris R, Kinne J, Wyns L, Muyldermans S. Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires. J Biol Chem. 2005;280:14114–14121. doi:10.1074/jbc.M413011200.
   PubMed Web of Science ®Google Scholar
• De Genst E, Chan PH, Pardon E, Hsu SD, Kumita JR, Christodoulou J, Menzer L, Chirgadze DY, Robinson CV, Muyldermans S, et al. A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation. J Phys Chem B. 2013;117:13245–13258. doi:10.1021/jp403425z.
   PubMed Web of Science ®Google Scholar
• Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature. 2003;424:783–788. doi:10.1038/nature01870.
   PubMed Web of Science ®Google Scholar
• Rouet R, Dudgeon K, Christie M, Langley D, Christ D. Fully human VH single domains that rival the stability and cleft recognition of camelid antibodies. J Biol Chem. 2015;290:11905–11917. doi:10.1074/jbc.M114.614842.
   PubMed Web of Science ®Google Scholar
• Conrath K, Pereira AS, Martins CE, Timoteo CG, Tavares P, Spinelli S, Kinne J, Flaudrops C, Cambillau C, Muyldermans S, et al. Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase. Protein Sci. 2009;18:619–628. doi:10.1002/pro.69.
   PubMed Web of Science ®Google Scholar
• Martin F, Volpari C, Steinkuhler C, Dimasi N, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R, Sollazzo M. Affinity selection of a camelized VH domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 1997;10:607–614.
   PubMedGoogle Scholar
• Perez C, Kohler M, Janser D, Pardon E, Steyaert J, Zenobi R, Locher KP. Structural basis of inhibition of lipid-linked oligosaccharide flippase PglK by a conformational nanobody. Sci Rep. 2017;7:46641. doi:10.1038/srep46641.
   PubMed Web of Science ®Google Scholar
• Rudolph MJ, Vance DJ, Cheung J, Franklin MC, Burshteyn F, Cassidy MS, Gary EN, Herrera C, Shoemaker CB, Mantis NJ. Crystal structures of ricin toxin’s enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies. J Mol Biol. 2014;426:3057–3068. doi:10.1016/j.jmb.2014.05.026.
   PubMed Web of Science ®Google Scholar
• Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure. 1999;7:361–370.
   PubMed Web of Science ®Google Scholar
• Jobling SA, Jarman C, Teh MM, Holmberg N, Blake C, Verhoeyen ME. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat Biotechnol. 2003;21:77–80. doi:10.1038/nbt772.
   PubMed Web of Science ®Google Scholar
• Hendrickx ML, A DEW, Buelens K, Compernolle G, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. J Thromb Haemost. 2011;9:2268–2277. doi:10.1111/j.1538-7836.2011.04495.x.
   PubMed Web of Science ®Google Scholar
• Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. J Thromb Haemost. 2010;8:1302–1312. doi:10.1111/j.1538-7836.2010.03816.x.
   PubMed Web of Science ®Google Scholar
• Ratier L, Urrutia M, Paris G, Zarebski L, Frasch AC, Goldbaum FA. Relevance of the diversity among members of the Trypanosoma cruzi trans-sialidase family analyzed with camelids single-domain antibodies. PLoS One. 2008;3:e3524. doi:10.1371/journal.pone.0003524.
   PubMed Web of Science ®Google Scholar
• Ardekani LS, Gargari SL, Rasooli I, Bazl MR, Mohammadi M, Ebrahimizadeh W, Bakherad H, Zare H. A novel nanobody against urease activity of Helicobacter pylori. Int J Infect Dis. 2013;17:e723–8. doi:10.1016/j.ijid.2013.02.015.
   PubMed Web of Science ®Google Scholar
• Kromann-Hansen T, Louise Lange E, Peter Sorensen H, Hassanzadeh-Ghassabeh G, Huang M, Jensen JK, Muyldermans S, Declerck PJ, Komives EA, Andreasen PA. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. Sci Rep. 2017;7:3385. doi:10.1038/s41598-017-03457-7.
   PubMed Web of Science ®Google Scholar
• Chan PH, Pardon E, Menzer L, De Genst E, Kumita JR, Christodoulou J, Saerens D, Brans A, Bouillenne F, Archer DB. A camelid-derived antibody fragment targeting the active site of a serine protease balances between inhibitor and substrate behavior. J Biol Chem. 2016;291:15156–15168. doi:10.1074/jbc.M116.732503.
   PubMed Web of Science ®Google Scholar
• Kaczmarek JZ, Skottrup PD. Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator. Mol Immunol. 2015;65:384–390. doi:10.1016/j.molimm.2015.02.011.
   PubMed Web of Science ®Google Scholar
• Arnon R. Enzyme inhibition by antibodies. Acta Endocrinol Suppl (Copenh). 1975;194:133–153.
   PubMedGoogle Scholar
• Farady CJ, Egea PF, Schneider EL, Darragh MR, Craik CS. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol. 2008;380:351–360. doi:10.1016/j.jmb.2008.05.009.
   PubMed Web of Science ®Google Scholar
• Wu Y, Eigenbrot C, Liang WC, Stawicki S, Shia S, Fan B, Ganesan R, Lipari MT, Kirchhofer D. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc Natl Acad Sci U S A. 2007;104:19784–19789. doi:10.1073/pnas.0708251104.
   PubMed Web of Science ®Google Scholar
• Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies: African trypanosomes as paradigm. J Biol Chem. 2004;279:1256–1261. doi:10.1074/jbc.M307341200.
   PubMed Web of Science ®Google Scholar
• Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH, Gupta A, Bai T, Murphy VJ, Anders RF, et al. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure. 2007;15:1452–1466. doi:10.1016/j.str.2007.09.011.
   PubMed Web of Science ®Google Scholar
• Ditlev SB, Florea R, Nielsen MA, Theander TG, Magez S, Boeuf P, Salanti A.. Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA. PLoS One. 2014;9:e84981. doi:10.1371/journal.pone.0084981.
   PubMed Web of Science ®Google Scholar
• Nunes-Silva S, Gangnard S, Vidal M, Vuchelen A, Dechavanne S, Chan S, Pardon E, Steyaert J, Ramboarina S, Chene A, et al. Llama immunization with full-length VAR2CSA generates cross-reactive and inhibitory single-domain antibodies against the DBL1X domain. Sci Rep. 2014;4:7373. doi:10.1038/srep07373.
   PubMed Web of Science ®Google Scholar
• Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol. 2008;82:12069–12081.
   PubMed Web of Science ®Google Scholar
• McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, Mortier D, Rutten L, Chander N, Edwards CJ, Ketteler R, et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med. 2012;209:1091–1103. doi:10.1084/jem.20112655.
   PubMed Web of Science ®Google Scholar
• Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS One. 2012;7:e33298. doi:10.1371/journal.pone.0033298.
   PubMed Web of Science ®Google Scholar
• McCoy LE, Rutten L, Frampton D, Anderson I, Granger L, Bashford-Rogers R, Dekkers G, Strokappe NM, Seaman MS, Koh W, et al. Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. 2014;10:e1004552. doi:10.1371/journal.ppat.1004552.
   PubMed Web of Science ®Google Scholar
• Acharya P, Luongo TS, Georgiev IS, Matz J, Schmidt SD, Louder MK, Kessler P, Yang Y, McKee K, O'Dell S, et al. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. J Virol. 2013;87:10173–10181. doi:10.1128/JVI.01332-13.
   PubMed Web of Science ®Google Scholar
• Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol. 2013;87:1137–1149. doi:10.1128/JVI.00461-12.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A. 2008;105:17121–17126. doi:10.1073/pnas.0805297105.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, Makiya M, Agulto L, Purcell RH, Chumakov K. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A. 2013;110:20242–20247. doi:10.1073/pnas.1320041110.
   PubMed Web of Science ®Google Scholar
• Puligedda RD, Kouiavskaia D, Adekar SP, Sharma R, Devi Kattala C, Rezapkin G, Bidzhieva B, Dessain SK, Chumakov K. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains. Antiviral Res. 2014;108:36–43. doi:10.1016/j.antiviral.2014.05.005.
   PubMed Web of Science ®Google Scholar
• Strauss M, Schotte L, Thys B, Filman DJ, Hogle JM. Five of five VHHs neutralizing poliovirus bind the receptor-binding site. J Virol. 2016;90:3496–3505. doi:10.1128/JVI.03017-15.
   PubMed Web of Science ®Google Scholar
• Koromyslova AD, Hansman GS. Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization. PLoS Pathog. 2017;13:e1006636. doi:10.1371/journal.ppat.1006636.
   PubMed Web of Science ®Google Scholar
• Shanker S, Czako R, Sapparapu G, Alvarado G, Viskovska M, Sankaran B, Atmar RL, Crowe JE, Jr., Estes MK, Prasad BV. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc Natl Acad Sci U S A. 2016;113:E5830–E7. doi:10.1073/pnas.1609990113.
   PubMed Web of Science ®Google Scholar
• Jahnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 2010;107:20565–20570. doi:10.1073/pnas.1012865107.
   PubMed Web of Science ®Google Scholar
• Delanote V, Janssen D, Van Hoorick D. Characterization of anti-Kv1.3 Nanobodies® and activity in inflammatory model systems. Poster presented at 12th Annual Ion Channel Retreat. Vancouver, British Columbia, Canada, 2014.
   Google Scholar
• Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M, Iacenda D, Knop JH, Hammel A, Bergmann P, et al. Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med. 2016;8:366ra162. doi:10.1126/scitranslmed.aaf0746.
   PubMed Web of Science ®Google Scholar
• Maussang D, Mujic-Delic A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem. 2013;288:29562–29572. doi:10.1074/jbc.M113.498436.
   PubMed Web of Science ®Google Scholar
• Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, Steyaert J, Parmentier M, Langer I. Development by genetic immunization of monovalent antibodies (nanobodies) behaving as antagonists of the human ChemR23 receptor. J Immunol. 2016;196:2893–2901. doi:10.4049/jimmunol.1500888.
   PubMed Web of Science ®Google Scholar
• Burg JS, Ingram JR, Venkatakrishnan AJ, Jude KM, Dukkipati A, Feinberg EN, Angelini A, Waghray D, Dror RO, Ploegh HL, et al. Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science. 2015;347:1113–1117. doi:10.1126/science.aaa5026.
   PubMed Web of Science ®Google Scholar
• Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, Kato HE, Livingston KE, Thorsen TS, Kling RC, et al. Structural insights into µ-opioid receptor activation. Nature. 2015;524:315–321. doi:10.1038/nature14886.
   PubMed Web of Science ®Google Scholar
• Hassaine G, Deluz C, Grasso L, Wyss R, Tol MB, Hovius R, Graff A, Stahlberg H, Tomizaki T, Desmyter A, et al. X-ray structure of the mouse serotonin 5-HT3 receptor. Nature. 2014;512:276–281. doi:10.1038/nature13552.
   PubMed Web of Science ®Google Scholar
• Ehrnstorfer IA, Geertsma ER, Pardon E, Steyaert J, Dutzler R. Crystal structure of a SLC11 (NRAMP) transporter reveals the basis for transition-metal ion transport. Nat Struct Mol Biol. 2014;21:990–996. doi:10.1038/nsmb.2904.
   PubMed Web of Science ®Google Scholar
• Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hubner H, Pardon E, Valant C, Sexton PM, et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature. 2013;504:101–106. doi:10.1038/nature12735.
   PubMed Web of Science ®Google Scholar
• Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011;477:549–555. doi:10.1038/nature10361.
   PubMed Web of Science ®Google Scholar
• Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature. 2011;469:175–180. doi:10.1038/nature09648.
   PubMed Web of Science ®Google Scholar
• Griffiths K, Dolezal O, Cao B, Nilsson SK, See HB, Pfleger KD, Roche M, Gorry PR, Pow A, Viduka K, et al. i-bodies, human single domain antibodies that antagonize chemokine receptor CXCR4. J Biol Chem. 2016;291:12641–12657. doi:10.1074/jbc.M116.721050.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Farenc C, Mahony J, Spinelli S, Bebeacua C, Blangy S, Veesler D, van Sinderen D, Cambillau C. Viral infection modulation and neutralization by camelid nanobodies. Proc Natl Acad Sci U S A. 2013;110:E1371–9. doi:10.1073/pnas.1301336110.
   PubMed Web of Science ®Google Scholar
• Khamrui S, Turley S, Pardon E, Steyaert J, Fan E, Verlinde CL, Bergman LW, Hol WG. The structure of the D3 domain of Plasmodium falciparum myosin tail interacting protein MTIP in complex with a nanobody. Mol Biochem Parasitol. 2013;190:87–91. doi:10.1016/j.molbiopara.2013.06.003.
   PubMed Web of Science ®Google Scholar
• Schmitz KR, Bagchi A, Roovers RC, Van Bergen En Henegouwen PM, Km F. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure. 2013;21:1214–1224. doi:10.1016/j.str.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017;8:14158. doi:10.1038/ncomms14158.
   PubMed Web of Science ®Google Scholar
• Rubinstein ND, Mayrose I, Halperin D, Yekutieli D, Gershoni JM, Pupko T. Computational characterization of B-cell epitopes. Mol Immunol. 2008;45:3477–3489. doi:10.1016/j.molimm.2007.10.016.
   PubMed Web of Science ®Google Scholar
• Dmitriev OY, Lutsenko S, Muyldermans S. Nanobodies as Probes for Protein Dynamics in Vitro and in Cells. J Biol Chem. 2016;291:3767–3775. doi:10.1074/jbc.R115.679811.
   PubMed Web of Science ®Google Scholar
• Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkonig A, Ruf A, Muyldermans S, Hol WG, Kobilka BK, Steyaert J. A general protocol for the generation of nanobodies for structural biology. Nat Protoc. 2014;9:674–693. doi:10.1038/nprot.2014.039.
   PubMed Web of Science ®Google Scholar
• MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. 1996;262:732–745. doi:10.1006/jmbi.1996.0548.
   PubMed Web of Science ®Google Scholar
• Nam DH, Rodriguez C, Remacle AG, Strongin AY, Ge X. Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries. Proc Natl Acad Sci U S A. 2016;113:14970–14975. doi:10.1073/pnas.1609375114.
   PubMed Web of Science ®Google Scholar
• Kirchhofer A, Helma J, Schmidthals K, Frauer C, Cui S, Karcher A, Pellis M, Muyldermans S, Casas-Delucchi CS, Cardoso MC, et al. Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol. 2010;17:133–138. doi:10.1038/nsmb.1727.
   PubMed Web of Science ®Google Scholar
• Chaikuad A, Keates T, Vincke C, Kaufholz M, Zenn M, Zimmermann B, Gutierrez C, Zhang RG, Hatzos-Skintges C, Joachimiak A, et al. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochem J. 2014;459:59–69. doi:10.1042/BJ20131399.
   PubMed Web of Science ®Google Scholar
• Adolf-Bryfogle J, Xu Q, North B, Lehmann A, Dunbrack RL Jr. PyIgClassify: a database of antibody CDR structural classifications. Nucleic Acids Res. 2015;43:D432–8. doi:10.1093/nar/gku1106.
   PubMed Web of Science ®Google Scholar
• Letunic I, Bork P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics. 2007;23:127–128. doi:10.1093/bioinformatics/btl529.
   PubMed Web of Science ®Google Scholar
• Govaert J, Pellis M, Deschacht N, Vincke C, Conrath K, Muyldermans S, Saerens D. Dual beneficial effect of interloop disulfide bond for single domain antibody fragments. J Biol Chem. 2012;287:1970–1979. doi:10.1074/jbc.M111.242818.
   PubMed Web of Science ®Google Scholar
• MacRaild CA, Richards JS, Anders RF, Norton RS. Antibody recognition of disordered antigens. Structure. 2016;24:148–157. doi:10.1016/j.str.2015.10.028.
   PubMed Web of Science ®Google Scholar
• Kuroda D, Gray JJ. Shape complementarity and hydrogen bond preferences in protein-protein interfaces: implications for antibody modeling and protein-protein docking. Bioinformatics. 2016;32:2451–2456. doi:10.1093/bioinformatics/btw197.
   PubMed Web of Science ®Google Scholar
• Fanning SW, Horn JR. An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop. Protein Sci. 2011;20:1196–1207. doi:10.1002/pro.648.
   PubMed Web of Science ®Google Scholar
• Haji-Ghassemi O, Blackler RJ, Martin Young N, Evans SV. Antibody recognition of carbohydrate epitopes. Glycobiology. 2015;25:920–952. doi:10.1093/glycob/cwv037.
   PubMed Web of Science ®Google Scholar
• Fleming JK, Wojciak JM, Campbell MA, Huxford T. Biochemical and structural characterization of lysophosphatidic acid binding by a humanized monoclonal antibody. J Mol Biol. 2011;408:462–476. doi:10.1016/j.jmb.2011.02.061.
   PubMed Web of Science ®Google Scholar
• Spinelli S, Frenken LG, Hermans P, Verrips T, Brown K, Tegoni M, Cambillau C. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry. 2000;39:1217–1222.
   PubMed Web of Science ®Google Scholar
• Spinelli S, Tegoni M, Frenken L, Van Vliet C, Cambillau C. Lateral recognition of a dye hapten by a llama VHH domain. J Mol Biol. 2001;311:123–129. doi:10.1006/jmbi.2001.4856.
   PubMed Web of Science ®Google Scholar
• De Genst EJ, Guilliams T, Wellens J, O'Day EM, Waudby CA, Meehan S, Dumoulin M, Hsu ST, Cremades N, Verschueren KH, et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol. 2010;402:326–343. doi:10.1016/j.jmb.2010.07.001.
   PubMed Web of Science ®Google Scholar
• Bever CS, Dong JX, Vasylieva N, Barnych B, Cui Y, Xu ZL, Hammock BD, Gee SJ. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem. 2016;408:5985–6002. doi:10.1007/s00216-016-9585-x.
   PubMed Web of Science ®Google Scholar
• El Khattabi M, Adams H, Heezius E, Hermans P, Detmers F, Maassen B, van der Ley P, Tommassen J, Verrips T, Stam J. Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications. Clin Vaccine Immunol. 2006;13:1079–1086. doi:10.1128/CVI.00107-06.
   PubMed Web of Science ®Google Scholar
• Gallo M, Kang JS, Pigott CR, Inventors; Innovative Targeting Solutions, Inc., Assignee. Sequence diversity generation in immunoglobulins. 2011. United States Patent US 8012714 B2.
   Google Scholar
• Drabek D, Janssens R, de Boer E, Rademaker R, Kloess J, Skehel J, Grosveld F. Expression cloning and production of human heavy-chain-only antibodies from murine transgenic plasma cells. Front Immunol. 2016;7:619. doi:10.3389/fimmu.2016.00619.
   PubMed Web of Science ®Google Scholar
• Yu GW, Vaysburd M, Allen MD, Settanni G, Fersht AR. Structure of human MDM4 N-terminal domain bound to a single-domain antibody. J Mol Biol. 2009;385:1578–1589. doi:10.1016/j.jmb.2008.11.043.
   PubMed Web of Science ®Google Scholar
• Ma X, Barthelemy PA, Rouge L, Wiesmann C, Sidhu SS. Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor. J Mol Biol. 2013;425:2247–2259. doi:10.1016/j.jmb.2013.03.020.
   PubMed Web of Science ®Google Scholar
• Walker A, Chung CW, Neu M, Burman M, Batuwangala T, Jones G, Tang CM, Steward M, Mullin M, Tournier N, et al. Novel interaction mechanism of a domain antibody-based inhibitor of human vascular endothelial growth factor with greater potency than ranibizumab and bevacizumab and improved capacity over aflibercept. J Biol Chem. 2016;291:5500–5511. doi:10.1074/jbc.M115.691162.
   PubMed Web of Science ®Google Scholar
• Yamniuk AP, Suri A, Krystek SR, Tamura J, Ramamurthy V, Kuhn R, Carroll K, Fleener C, Ryseck R, Cheng L, et al. Functional antagonism of human CD40 achieved by targeting a unique species-specific epitope. J Mol Biol. 2016;428:2860–2879. doi:10.1016/j.jmb.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Gunn RJ, Herrin BR, Acharya S, Cooper MD, Wilson IA. VLR recognition of TLR5 expands the molecular characterization of protein antigen binding by non-Ig-based antibodies. J Mol Biol. 2018;430:1350–1367. doi:10.1016/j.jmb.2018.03.016.
   PubMed Web of Science ®Google Scholar